other material
confidence high
sentiment positive
materiality 0.65
Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025
Keros Therapeutics, Inc.
- Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
- Enrolled 113 patients, exceeding the initial target of 90 patients.
- Topline data expected to be presented in the second quarter of 2025.
- Trial evaluates cibotercept in combination with background therapy.